K. Suenaga et al., Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria, EXP HEMATOL, 29(5), 2001, pp. 639-642
Objective. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal
hematopoietic stem cell disorder that manifests as hemolytic anemia, venous
thrombosis, and deficient hematopoiesis. Although allogeneic hematopoietic
stem cell transplantation is considered the only curative therapeutic meas
ure, transplant-related mortality is not negligible. Several studies suppor
ted the use of nonmyeloablative stem cell transplantation (NST) for patient
s of advanced age or with organ dysfunction, Hence, we used NST in a PNH pa
tient who suffered from acute renal failure due to repeated episodes of hem
olysis,
Materials and Methods We performed NST using a conditioning regimen consist
ing of cladribine 0.11 mg/kg X 6, busulfan 4 mg/kg x 2, and rabbit anti-thy
mocyte globulin 2.5 mg/kg x 2. He received peripheral blood stem cells from
his human leukocyte antigen-matched brother. Prophylaxis against graft-vs-
host disease was performed with cyclosporine A alone, Chimerism of peripher
al blood mononuclear cells was evaluated serially using short tandem repeat
analysis and flow cytometry,
Results. No meaningful regimen-related toxicities were documented. Donor ch
imerism of 90 to 100% was achieved on day 14 and thereafter. The patient is
doing well, without any recurrence of hemolysis 6 months after transplant,
Follow-up chimerism studies confirmed stable and functioning donor-type he
matopoiesis,
Conclusions. NST may become a safe and curative approach in patients with P
NH, Further studies are needed to establish the role of NST for treatment o
f PNH. (C) 2001 International Society for Experimental Hematology, Publishe
d by Elsevier Science Inc.